A perilous path: the inborn errors of sphingolipid metabolism

Area of Science:

• Biochemistry
• Genetics
• Molecular Biology

Background:

• The sphingolipid (SL) metabolic pathway is fundamental in mammalian cells, producing lipids with roles in cell membranes and signaling.
• Historically, genetic defects in SL metabolism were primarily linked to lysosomal degradation; however, recent gene discoveries reveal broader implications.
• Mutations across the entire SL pathway, including synthesis and degradation, are now recognized as causes of genetic disorders.

Purpose of the Study:

• To review the expanding understanding of genetic disorders arising from the sphingolipid metabolic pathway.
• To elucidate common pathogenic mechanisms underlying diverse inborn errors of SL metabolism.
• To explore the potential role of SL pathway gene variants in common diseases like Parkinson's and asthma.

Main Methods:

• Literature review and synthesis of current research on sphingolipid metabolism and associated genetic disorders.
• Analysis of pathogenic mechanisms, including lipid accumulation and disruption of cellular processes.
• Examination of clinical heterogeneity and affected physiological systems in inborn errors of SL metabolism.

Main Results:

• Genetic disorders are caused by mutations in various parts of the SL pathway, not just lysosomal degradation.
• Common pathogenic mechanisms involve the overaccumulation of bioactive lipids and the disruption of critical cellular functions.
• The nervous system and skin are frequently affected in these disorders, highlighting shared physiological impacts.
• Gene variants in the SL pathway are associated with increased susceptibility to complex diseases such as Parkinson's disease and childhood asthma.

Conclusions:

• Inborn errors of sphingolipid metabolism are clinically diverse but share underlying pathogenic mechanisms.
• Understanding these disorders offers insights into the interplay between rare genetic conditions and common diseases.
• Further research into the SL metabolic pathway may reveal novel therapeutic targets for both rare and common human diseases.